AnaptysBio (ANAB)
NASDAQ:ANAB
Want to see ANAB full AI Analyst Report?
ANAB Stock Chart & Stats
$67.51
-$0.23(-1.55%)
At close: 4:00 PM EST
$67.51
-$0.23(-1.55%)
Day’s Range― - ―
52-Week Range$17.11 - $73.30
Previous CloseN/A
Volume154.73K
Average Volume (3M)647.27K
Market Cap
$1.49B
Enterprise Value$2.43B
Total Cash (Recent Filing)$286.45M
Total Debt (Recent Filing)$277.36M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 10, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding29,100,903
10 Day Avg. Volume547,966
30 Day Avg. Volume647,269
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)24.14
Price to Sales (P/S)3.83
P/FCF Ratio45.80
Enterprise Value/Market Cap1.63
Enterprise Value/Revenue10.45
Enterprise Value/Gross Profit8.98
Enterprise Value/Ebitda45.55
Forecast
1Y Price Target
$73.89Price Target Upside9.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.04
Revenue Forecast (FY)$125.27M
Bulls Say, Bears Say
Bulls Say
Royalty-focused Business Model After First Tracks Spin-offShifting to a royalty-centric model materially reduces upstream R&D expense and operating complexity, converting Anaptys into a cash-flow oriented steward of partnered revenue. Over 2–6 months this structural change should lower burn, stabilize operating costs, and align incentives toward recurring royalty monetization.
Improved Operating Cash Generation In 2025A return to positive operating and free cash flow demonstrates the company can generate internal cash rather than rely solely on financing. Even if TTM cash dropped, the 2025 improvement indicates underlying cash-generation capability that supports royalty payments, governance costs, and limited capital needs.
Strengthened Financial Leadership And Board OversightBringing in a seasoned CFO and adding independent board members improves financial stewardship, risk management and investor communication during a strategic transition. Stronger governance reduces execution risk as the firm shifts to royalty management and navigates transitional agreements and reporting cadence changes.
Bears Say
Deteriorated Balance Sheet And Higher LeverageA materially weaker balance sheet and rising leverage reduce the company's financial flexibility and increase vulnerability to adverse timing of partner payments. For a royalty-focused company, constrained equity and higher debt raise refinancing and covenant risk, limiting ability to absorb shocks or pursue opportunistic investments.
Lumpy, Volatile Revenue And Cash Flows Tied To Partner/milestone TimingDependence on milestone and partner-sourced receipts creates unpredictability in revenue and cash flow. That lumpiness complicates planning for a royalties-driven entity, making near-term distributions, debt service and working capital sensitive to irregular payment timing rather than steady product sales.
Spin-off Removed R&D Assets And Cash, Increasing Dependency On Royalties/partnersSeparating development assets and cash reduces diversification of future growth drivers and leaves Anaptys reliant on third-party execution and partner royalty streams. Long-term upside is constrained without internal programs, making returns contingent on counterparties' commercialization success and contract terms.
AnaptysBio News
ANAB FAQ
What was AnaptysBio’s price range in the past 12 months?
AnaptysBio lowest stock price was $17.11 and its highest was $73.30 in the past 12 months.
What is AnaptysBio’s market cap?
AnaptysBio’s market cap is $1.49B.
When is AnaptysBio’s upcoming earnings report date?
AnaptysBio’s upcoming earnings report date is Aug 10, 2026 which is in 67 days.
How were AnaptysBio’s earnings last quarter?
AnaptysBio released its earnings results on May 12, 2026. The company reported -$1.84 earnings per share for the quarter, missing the consensus estimate of -$0.644 by -$1.196.
Is AnaptysBio overvalued?
According to Wall Street analysts AnaptysBio’s price is currently Undervalued.
Does AnaptysBio pay dividends?
AnaptysBio does not currently pay dividends.
What is AnaptysBio’s EPS estimate?
AnaptysBio’s EPS estimate is -0.27.
How many shares outstanding does AnaptysBio have?
AnaptysBio has 29,100,903 shares outstanding.
What happened to AnaptysBio’s price movement after its last earnings report?
AnaptysBio reported an EPS of -$1.84 in its last earnings report, missing expectations of -$0.644. Following the earnings report the stock price went down -4.414%.
Which hedge fund is a major shareholder of AnaptysBio?
Currently, no hedge funds are holding shares in ANAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AnaptysBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$73.89 (9.45% Upside)
$73.89 (9.45% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 135.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
226.84%
12-Months-Change
Fundamentals
Return on Equity
442.91%
Trailing 12-Months
Asset Growth
-21.89%
Trailing 12-Months
Company Description
AnaptysBio
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB Stock 12 Month Forecast
Average Price Target
$73.89
▲(9.45% Upside)
Technical Analysis
Meiragtx Holdings
―
Keros Therapeutics
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
―
Ownership Overview
2.26% Insiders
11.84% Mutual Funds
51.26% Other Institutional Investors
22.32% Public Companies and
Individual Investors